214 related articles for article (PubMed ID: 24698599)
1. The use of eplerenone in therapy-resistant chronic central serous chorioretinopathy.
Breukink MB; den Hollander AI; Keunen JE; Boon CJ; Hoyng CB
Acta Ophthalmol; 2014 Sep; 92(6):e488-90. PubMed ID: 24698599
[No Abstract] [Full Text] [Related]
2. Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy: a pilot study.
Bousquet E; Beydoun T; Zhao M; Hassan L; Offret O; Behar-Cohen F
Retina; 2013; 33(10):2096-102. PubMed ID: 23719402
[TBL] [Abstract][Full Text] [Related]
3. Oral eplerenone for treatment of chronic central serous chorioretinopathy: a case series.
Salz DA; Pitcher JD; Hsu J; Regillo CD; Fineman MS; Elliott KS; Vander JF; Fischer DH; Spirn MJ
Ophthalmic Surg Lasers Imaging Retina; 2015 Apr; 46(4):439-44. PubMed ID: 25970864
[TBL] [Abstract][Full Text] [Related]
4. CENTRAL SEROUS CHORIORETINOPATHY TREATED WITH MINERALOCORTICOID ANTAGONISTS: A ONE-YEAR PILOT STUDY.
Ghadiali Q; Jung JJ; Yu S; Patel SN; Yannuzzi LA
Retina; 2016 Mar; 36(3):611-8. PubMed ID: 26405766
[TBL] [Abstract][Full Text] [Related]
5. A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROL PILOT STUDY OF EPLERENONE FOR THE TREATMENT OF CENTRAL SEROUS CHORIORETINOPATHY (ECSELSIOR).
Rahimy E; Pitcher JD; Hsu J; Adam MK; Shahlaee A; Samara WA; Vander JF; Kaiser RS; Chiang A; Spirn MJ; Fineman MS
Retina; 2018 May; 38(5):962-969. PubMed ID: 28426624
[TBL] [Abstract][Full Text] [Related]
6. Clinical experience with eplerenone to treat chronic central serous chorioretinopathy.
Cakir B; Fischer F; Ehlken C; Bühler A; Stahl A; Schlunck G; Böhringer D; Agostini H; Lange C
Graefes Arch Clin Exp Ophthalmol; 2016 Nov; 254(11):2151-2157. PubMed ID: 27145785
[TBL] [Abstract][Full Text] [Related]
7. SPIRONOLACTONE FOR NONRESOLVING CENTRAL SEROUS CHORIORETINOPATHY: A RANDOMIZED CONTROLLED CROSSOVER STUDY.
Bousquet E; Beydoun T; Rothschild PR; Bergin C; Zhao M; Batista R; Brandely ML; Couraud B; Farman N; Gaudric A; Chast F; Behar-Cohen F
Retina; 2015 Dec; 35(12):2505-15. PubMed ID: 26017871
[TBL] [Abstract][Full Text] [Related]
8. Systemic Mineralocorticoid Antagonists in the Treatment of Central Serous Chorioretinopathy.
Yang D; Eliott D
Semin Ophthalmol; 2017; 32(1):36-42. PubMed ID: 27929707
[TBL] [Abstract][Full Text] [Related]
9. Eplerenone in patients with chronic recurring central serous chorioretinopathy.
Leisser C; Hirnschall N; Hackl C; Plasenzotti P; Findl O
Eur J Ophthalmol; 2016 Aug; 26(5):479-84. PubMed ID: 26692062
[TBL] [Abstract][Full Text] [Related]
10. A new treatment approach - Eplerenone - in central serous chorioretinopathy - Case report.
Cioboata M; Alexandrescu C; Hopinca CA; Pienaru MC; Merticariu A; Schmitzer S
J Med Life; 2016; 9(1):92-94. PubMed ID: 27713772
[TBL] [Abstract][Full Text] [Related]
11. Eplerenone for chronic central serous chorioretinopathy-a randomized controlled prospective study.
Schwartz R; Habot-Wilner Z; Martinez MR; Nutman A; Goldenberg D; Cohen S; Shulman S; Guzner-Gur H; Loewenstein A; Goldstein M
Acta Ophthalmol; 2017 Nov; 95(7):e610-e618. PubMed ID: 28653813
[TBL] [Abstract][Full Text] [Related]
12. OCT-A in chronic central serous chorioretinopathy treated with oral eplerenone and half-fluence photodynamic therapy: A comparative study.
Uzun S; Uzun F; Ercal O
Eur J Ophthalmol; 2024 May; 34(3):NP131. PubMed ID: 37899582
[No Abstract] [Full Text] [Related]
13. Mineralocorticoid Antagonists in the Treatment of Central Serous Chorioretinopathy: A Comparative Analysis.
Kapoor KG; Wagner AL
Ophthalmic Res; 2016; 56(1):17-22. PubMed ID: 26982318
[TBL] [Abstract][Full Text] [Related]
14. MINERALOCORTICOID RECEPTOR ANTAGONIST TREATMENT IN BILATERAL CHRONIC CENTRAL SEROUS CHORIORETINOPATHY: A COMPARATIVE STUDY OF EXUDATIVE AND NONEXUDATIVE FELLOW EYES.
Gergely R; Kovács I; Schneider M; Resch M; Papp A; Récsán Z; Nagy ZZ; Ecsedy M
Retina; 2017 Jun; 37(6):1084-1091. PubMed ID: 27627749
[TBL] [Abstract][Full Text] [Related]
15. Spironolactone versus observation in the treatment of acute central serous chorioretinopathy.
Sun X; Shuai Y; Fang W; Li J; Ge W; Yuan S; Liu Q
Br J Ophthalmol; 2018 Aug; 102(8):1060-1065. PubMed ID: 29089356
[TBL] [Abstract][Full Text] [Related]
16. SPIRONOLACTONE AS A THERAPEUTIC ALTERNATIVE FOR THE BULLOUS VARIANT OF CENTRAL SEROUS CHORIORETINOPATHY.
Ramos-Yau EC; Muñoz-Domínguez E; Contreras-Mérida SP; Valencia-Londoño LM
Retin Cases Brief Rep; 2020; 14(4):381-385. PubMed ID: 29595560
[TBL] [Abstract][Full Text] [Related]
17. Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy.
Zhao M; Célérier I; Bousquet E; Jeanny JC; Jonet L; Savoldelli M; Offret O; Curan A; Farman N; Jaisser F; Behar-Cohen F
J Clin Invest; 2012 Jul; 122(7):2672-9. PubMed ID: 22684104
[TBL] [Abstract][Full Text] [Related]
18. [Eplerenone treatment in chronic central serous chorioretinopathy].
Sampo M; Soler V; Gascon P; Ho Wang Yin G; Hoffart L; Denis D; Matonti F
J Fr Ophtalmol; 2016 Jun; 39(6):535-42. PubMed ID: 27230892
[TBL] [Abstract][Full Text] [Related]
19. The use of mineralocorticoid receptor antagonists in chronic central serous chorioretinopathy.
Pociej-Marciak W; Karska-Basta I; Ozog-Baran J; Kubicka-Trzaska A; Filemonowicz-Skoczek A; Romanowska-Dixon B
Klin Oczna; 2016 Aug; 118(1):48-54. PubMed ID: 29715409
[TBL] [Abstract][Full Text] [Related]
20. Predictive Factors of Response to Mineralocorticoid Receptor Antagonists in Nonresolving Central Serous Chorioretinopathy.
Bousquet E; Dhundass M; Lejoyeux R; Shinojima A; Krivosic V; Mrejen S; Gaudric A; Tadayoni R
Am J Ophthalmol; 2019 Feb; 198():80-87. PubMed ID: 30308202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]